CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Modification of Hinge/Transmembrane and Signal Transduction Domains Improves the Expression and Signaling Threshold of GXMR-CAR Specific to Cryptococcus spp.
Modification of Hinge/Transmembrane and Signal Transduction Domains Improves the Expression and Signaling Threshold of GXMR-CAR Specific to Cryptococcus spp.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
嵌合抗原受体(CAR)可重定向T细胞,使其识别特定靶点。CAR各组成部分在抗原特异性、结构稳定性、细胞表面表达和诱导细胞活化方面发挥关键作用,共同决定CAR-T 细胞治疗成败。靶向B细胞淋巴瘤的CAR产品推动了CAR应用向癌症以外领域发展。例如,我们团队开发了一种特异性靶向隐球菌属荚膜葡萄糖醛木甘露聚糖(GXM)的CAR,称为GXMR-CAR或GXMR-IgG4-28。隐球菌是真菌,可导致危及生命的隐球菌病;GXMR-IgG4-28可重定向T细胞靶向隐球菌属酵母和巨型细胞形式。本文将GXMR-CAR中IgG4铰链及CD28跨膜结构域替换为CD8分子的铰链/跨膜结构域,并分别使用CD28或4-1BB作为共刺激结构域,构建GXMR-8-28和GXMR-8-BB。表达含CD8铰链/跨膜结构域GXMR-CAR的Jurkat细胞CAR表达提高,并诱导基础信号传导。存在新型隐球菌和格特隐球菌参考菌株时,GXMR-8-28和GXMR-8-BB可诱导高水平IL-2并上调CD69表达。
此外,与临床分离的隐球菌属菌株孵育后,GXMR-8-28和GXMR-8-BB反应强度增加,其中4-1BB共刺激结构域触发的细胞活化更明显。酪氨酸激酶抑制剂达沙替尼可在有无配体情况下减弱GXMR-CAR信号级联激活。
本研究优化了含CD8铰链/跨膜结构域的新型第二代GXMR-CAR,改善了CAR表达、抗原识别以及T细胞活化信号强度。
Chimeric antigen receptors (CARs) redirect T cells to recognize a specific target. CAR components play a pivotal role in antigen specificity, structure stability, expression on cell surface, and induction of cellular activation, which together determine the success of CAR T-cell therapy. CAR products targeting B-cell lymphoma encouraged the development of new CAR applications beyond cancer.
For example, our group developed a CAR to specifically target glucuronoxylomannan (GXM) in the capsule of Cryptococcus species, called GXMR-CAR or GXMR-IgG4-28 . Cryptococcus are fungi that cause the life-threatening disease cryptococcosis, and GXMR-IgG4-28 redirected T cells to target yeast and titan cell forms of Cryptococcus spp.
Here, we replaced the IgG4-hinge and CD28-transmembrane domains from GXMR-CAR with a CD8 molecule as the hinge/transmembrane and used CD28 or 4-1BB molecules as co-stimulatory domains, creating GXMR-8-28 and GXMR-8-BB , respectively. Jurkat cells expressing GXMR-CAR containing CD8 as the hinge/transmembrane improved the CAR expression and induced a tonic signaling. GXMR-8-28 and GXMR-8-BB induced high levels of IL-2 and up-regulation of CD69 expression in the presence of reference strains of C. neoformans and C. gattii .
Moreover, GXMR-8-28 and GXMR-8-BB showed increased strength in response to incubation with clinical isolates of Cryptococcuss spp. , and 4-1BB co-stimulatory domain triggered a more pronounced cellular activation. Dasatinib, a tyrosine kinase inhibitor, attenuated the GXMR-CAR signaling cascade's engagement in the presence or absence of its ligand.
This study optimized novel second-generation GXMR-CARs containing the CD8-hinge/transmembrane domain that improved CAR expression, antigen recognition, and signal strength in T-cell activation.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。